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ABSTRACT
Objectives: To study the expression of adhesion
molecules in patients with systemic sclerosis (SSc) with
and without pulmonary arterial hypertension (PAH) and
the effects of therapy with the endothelin-1 (ET-1)
receptor antagonist, bosentan.
Methods: In all, 35 patients with SSc and 25 healthy
donors (HD) were selected for this study. Of 35 patients,
10 had isolated PAH assessed by Doppler echocardio-
graphy and treated with bosentan. Peripheral blood (PB)
lymphocytes were isolated by density gradient centrifu-
gation, and the expression of lymphocyte function-
associated antigen-1 (LFA-1), very late antigen-4 (VLA-4)
and L-selectin on CD3 T cells was assessed by double
immunofluorescence and flow-cytometry. As endothelial
activation markers, serum soluble P-selectin, platelet/
endothelial cell adhesion molecule (PECAM)-1, vascular
cell adhesion molecule (VCAM)-1, intercellular adhesion
molecule (ICAM)-1 and von Willebrand factor (vWF)
antigen were assessed by ELISA. In patients with SSc-
PAH, T cell subsets and soluble endothelial markers were
assessed at baseline and after 6 and 12 months of
bosentan therapy.
Results: In patients with SSc-PAH, serum soluble ICAM-
1, VCAM-1, P-selectin and PECAM-1 levels were higher
than in HD at baseline and fell to normal values after
12 months of bosentan therapy. CD3–LFA1 T cells were
significantly higher in PAH-SSc at baseline than in HD or
SSc and significantly decreased after therapy. CD3–L-
selectin T cells were significantly lower in SSc-PAH at
baseline than in HD or SSc and rose to normal levels after
bosentan therapy.
Conclusions: This study confirms that endothelial
activation occurs in SSc, and suggests that changes in
the T cell/endothelium interplay take place in SSc-
associated PAH. Bosentan seems to be able to hamper
these changes and restore T cell functions in these
patients.
A crucial role in the pathogenesis of systemic
sclerosis (SSc) seems to be played by the interac-
tions occurring between endothelial cells and
T cells. Endothelial cells, after metabolic activation,
produce an array of cytokines and growth factors
and promote immune cells to adhere and migrate
through the vessel wall into the extra-vascular
space. This leads to fibroblasts and myoblasts
activation and changes in extracellular matrix
(ECM) remodelling, resulting in an excessive
accumulation of ECM components that causes
fibrosis of the skin and internal organs and
hypertrophy/hyperplasia of the arterial wall of
pulmonary and renal vessels.
1 Circulating periph-
eral blood T cells adhere to endothelial cells by
means of an intricate system of adhesion molecules
whose expression increases on the cell surface
following activation. Lymphocyte function-asso-
ciated antigen-1 (LFA-1), very late antigen-4 (VLA-4)
and L-selectin are expressed on lymphocytes,
while their counter-receptors intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and CD34/endoglycan are
expressed on endothelial cells.
2 When overex-
pressed on the activated endothelial layer,
VCAM-1, ICAM-1 as well as P-selectin and platelet
endothelial cell adhesion molecule-1 (PECAM-1)
undergo shedding and their soluble forms,
sVCAM-1, sICAM-1, sP-selectin and sPECAM-1,
respectively, are detectable in serum and consid-
ered to be markers of endothelial cell activity or
injury. There is a growing body of evidence that
these endothelial activation markers are raised in
patients with SSc and that their levels correlate
with disease activity and can be regulated by
therapy.
3
Endothelin-1 (ET-1) is a potent mitogenic factor
mainly produced by endothelial cells, and exerts its
biological activity by interacting with two cell
membrane-bound receptors named ETA and ETB,
expressed on different cells, such as endothelial
cells, smooth muscle cells and fibroblasts.
4 ET-1 has
pleiotropic functions, being a potent vasoconstric-
tor, and stimulates synthesis and accumulation of
ECM proteins by fibroblasts and smooth muscle
cells. Since its levels have been found to be
increased in SSc, it is believed to have a key role
in the pathogenesis of this disease.
5 In particular,
ET-1 levels have been detected in lung plexiform
lesions in patients with pulmonary arterial hyper-
tension (PAH) and there is evidence from experi-
mental models and clinical studies that ET-1 is
directly involved in promoting the remodelling of
vessel walls leading to an increase of peripheral
vascular resistance and hence a rise in pulmonary
arterial pressure.
6 Recently, a dual endothelin
receptor antagonist named bosentan has been
shown to be effective and safe for the treatment
of patients with SSc with PAH.
7 In this study, the
biological outcome of bosentan on endothelial
activity and T cell activation has been evaluated
in patients with SSc-associated PAH. Expression of
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blood T cells in patients with SSc-PAH at baseline and after
bosentan treatment. Serum levels of soluble VCAM-1, ICAM-1,
P-selectin, PECAM-1 and von Willebrand factor (vWF) were
also assessed.
METHODS
Patients
A total of 35 patients with SSc were consecutively recruited at
the Rheumatology Unit of the University of Bari, Bari, Italy.
Mean age was 51.4 years (range 27–75) and mean disease
duration was 10.4 years (range 1–28). All the patients were
assigned to the limited cutaneous subset, according to the Leroy
subset classification.
8 A total of 25 healthy donors (HD), coming
from the same geographic area and attending the Rheumatology
Unit as students, teachers and employers, were enrolled on the
basis of their age (mean age 46.7 years, range 25–69). In the
patients with SSc, high-resolution chest tomography was
carried out to assess interstitial lung fibrosis, as well as
respiratory function tests to evaluate pulmonary forced vital
capacity (FVC) and alveolar CO diffusion (DLCO), along with
full blood count, renal function tests, serum complement levels,
liver enzymes, erythrocyte sedimentation rate (ESR). Of 35
patients, 10 had isolated PAH assessed by Doppler echocardio-
graphy (tricuspid gradient at rest .35 mmHg), and subse-
quently confirmed by right heart catheterisation; mean
pulmonary artery pressure (mPAP) was 38.6 (9) mmHg,
pulmonary vascular resistance was 758 (254) dyne/s/cm,
pulmonary capillary wedge pressure was 13 (1.7) mmHg.
Patients with SSc-PAH were in New York Heart Association
(NYHA) functional classes II–III according to the World Health
Organization (WHO) classification, with 6-min walking dis-
tance (6-MWD) ranging between 60 and 450 m.
7 No patient
had left ventricular disease at Doppler echocardiography.
Further characteristics of the patients with SSc with PAH are
shown in detail in table 1. Patients with SSc-PAH were treated
with bosentan at the standard dosage of 62.5 mg twice daily for
4 weeks, followed by 125 mg twice daily for 50 weeks.
Additional permitted drugs were intestinal prokinetics and
H-2 blockers. No patients were on steroids and/or immunosup-
pressive agents. Clinical assessment, including 6-MWD and
Doppler echocardiography, and collection of serum and heparin
blood samples were performed at baseline and after 6 and
12 months of bosentan therapy. Written informed consent was
obtained from all patients and healthy donors according to the
declaration of Helsinki and the study was approved by the
Ethics Committee of the Policlinico di Bari.
T lymphocyte phenotype
Peripheral blood (PB) lymphocytes were isolated by gradient
density separation on lymphoprep and cell surface antigen
expression on T cells was assessed by double immunoflores-
cence. Briefly, 5610
5 cells were incubated with 5 ml of mAb
(CD3–PE, CD11a/LFA1-FITC, CD49d/VLA4-FITC, CD62L/
L-selectin-FITC, Immunotech, Marseille, France) for 209 on
ice, washed twice and T cell subsets were evaluated by flow
cytometry (FACScan, Becton Dickinson, Franklin Lakes,
New Jersey, USA). T cell phenotype was evaluated at each
timepoint on freshly isolated lymphocytes against a control
sample, incubated with rat IgG1-FITC/IgG2-PE (DAKO,
Glostrup, Denmark).
Soluble endothelial activation markers
Serum levels of endothelial markers were assessed by commer-
cial ELISA: sICAM-1 ELISA kit (Cellular Communication
Investigation, Immunotech, Marseille, France), sVCAM-1
ELISA kit (Immuno Biological Laboratories, Hamburg,
Germany), vWF ELISA kit (Gentaur, Brussels, Belgium),
sPECAM-1 ELISA kit (Bender MedSystems, Wien, Austria)
and sP-selectin ELISA kit (Bender MedSystems), following the
manufacturers’ instructions. ELISA experiments were run
simultaneously on all samples previously frozen at 230uC.
Statistical analysis
Values are expressed as mean 1 SD) unless otherwise indicated.
Analysis of variance (ANOVA) with the post hoc least square
differences (LSD) range test was used to compare the different
groups at baseline, whereas a paired Student t test was applied
to compare patients with SSc-PAH at the different timepoints.
The Mann–Whitney U test was used to compare NYHA
functional classes over time. Correlations of clinical data with
endothelial activation markers and T cell phenotype were
carried out using Pearson or Spearman analysis. The significance
level was set at p,0.05.
RESULTS
Clinical outcomes
Bosentan treatment significantly improved exercise ability in
patients with SSc-PAH with 6-MWD, which rose from 267
(33) m at baseline to 359 (27) m at 6 months and to 376 (40) m
at 12 months (p,0.05 vs baseline). Bosentan also induced an
improvement of dyspnoea, measured by NYHA, with a
significant reduction of the NYHA functional class, observed
after 12 months of therapy (median baseline 2.0 vs median
12 months 1.5, p,0.05). PAP values reduced during bosentan
treatment, without reaching statistical significance (data not
shown). Digital ulcers were present in 8 out of 10 patients and 6
patients did not experience new digital ulcers during bosentan
therapy.
Adhesion molecule expression on T cells
Absolute number of lymphocytes did not change upon bosentan
therapy. As shown in fig 1A, PB T cells expressing LFA-1 were
significantly higher in patients with SSc-PAH at baseline (mean
(SD) 46.3 (6)%) than in HD (32.6 (3)%, p,0.05) or in patients
with SSc without PAH (35.8 (5)%, p,0.05). They decreased
after 6 months of bosentan therapy (35.5 (5)%, p,0.05 vs
baseline) and fell to normal values after 12 months (32.7 (4)%,
p,0.05 vs baseline). The proportion of T cells bearing VLA-4
antigen (fig 1B) was significantly reduced in the SSc-PAH group
(73.4 (4)%) in comparison with HD (83.3 (6)%, p,0.05) and
patients with SSc without PAH (84.8 (5)%, p,0.05), but was
Table 1 Patient characteristics
Parameter Value
Patients with PAH 10
Age, years 56.4 (31–79)
Disease duration, years 10.2 (2–24)
FVC/DLCO ratio 1.6 (1.37–2.13)
ANA (n) 10
SCL70 (n) 2
ACA (n) 2
Values are mean (range).
ACA, anticentromere antibodies; ANA, antinuclear antibodies; DLCO, CO diffusion;
FVC, forced vital capacity; PAH, pulmonary arterial hypertension.
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not significant vs baseline) nor after 12 months (75.1 (2)%, not
significant vs baseline). Expression of L-selectin on T cells
(fig 1C) was significantly lower in patients with SSc-PAH (26.4
(8)%) than in the HD group (75.5 (8)%, p,0.01) or in patients
with SSc without PAH (75.5 (2)%, p,0.01), and gradually rose
following bosentan treatment at the 6 months (43.1 (10)%,
p,0.05 vs baseline) and 12 months controls (63.2 (6)%, p,0.01
vs baseline). In fig 2, the representative histograms of the
fluorescence intensity for CD3–L-selectin cell subset from a
patient with SSc-PAH before and after bosentan therapy, a
patient with SSc without PAH and a healthy donor are shown.
Serum endothelial markers
Serum levels of soluble vWF (fig 3A) were increased in patients
with SSc-PAH (1043 (97) mU/ml) and patients with SSc
without PAH (1061 (86) mU/ml) in comparison with the HD
group (770 (54) mU/ml, p,0.05) and did not change after
12 months of bosentan therapy (980 (89) mU/ml, not signifi-
cant vs baseline). Serum levels of sP-selectin (fig 3B) were
significantly higher in the SSc-PAH group (367 (42) ng/ml) and
in patients with SSc without PAH (362 (61) ng/ml) than in HD
(132 (12) ng/ml, p,0.01), and significantly decreased after
12 months of bosentan therapy (211 (31) ng/ml, p,0.05, vs
baseline). Soluble PECAM serum levels were similar in patients
with SSc-PAH (48.7 (3) ng/ml), in patients with SSc without
PAH (46.7 (4) ng/ml) and in HD (41.1 (2) ng/ml) and were not
modulated by bosentan treatment (37.7 (4) ng/ml). Serum
levels of sVCAM-1 (fig 3C) were significantly higher in patients
with SSc without PAH (300 (16) ng/ml) than in the HD group
(261 (9) ng/ml, p,0.05), and were also increased in patients
with SSc-PAH (303 (3) ng/ml) but without reaching statistical
significance. However, sVCAM-1 levels significantly dropped
after 12 weeks of bosentan therapy (229 (15) ng/ml, p,0.01 vs
baseline). Furthermore, sICAM-1 serum levels (fig 3D) were
significantly higher in patients with SSc-PAH (2536 (647) pg/
ml) and patients with SSc without PAH (3293 (1006) pg/ml)
than in HD (588 (48) pg/ml, p,0.01), and declined to normal
levels following bosentan treatment (696 (98) pg/ml, p,0.05 vs
baseline). Finally, soluble PECAM levels (fig 3E) were increased
in patients with SSc-PAH (46.7 (4) ng/ml) in comparison with
HD (41 (2) ng/ml), but the difference was not statistically
significant and significantly reduced after bosentan treatment
(37 (3) ng/ml; p,0.05).
No significant correlations were found between adhesion
molecules, either soluble or expressed on T cells, and clinical
parameters such as modified Rodnan skin score, 6-MWD,
NYHA classes, new digital ulcers, FVC and DLCO.
Furthermore, no correlations between adhesion molecule
changes over time and treatment response were detected.
DISCUSSION
The pathophysiology of SSc is multifaceted and different types
of cells, such as fibroblasts, immune cells, inflammatory cells,
endothelial cells, smooth muscle cells, pericytes, myointimal
cells, are involved. Each disease picture is unique because the
pathological process may lead to different tissue damage
depending on the organ involved.
1 In recent years, the study
of pulmonary vasculature involvement has posed a strong
challenge since PAH dramatically affects the clinical outcome
and survival of patients with SSc, especially those classified
within the limited cutaneous subset.
9
A widely accepted hypothesis is that, maybe on a genetic
basis and following unknown external stimuli, endothelial cells
and lymphocytes become activated and stimulate fibroblasts
and smooth muscle cells to proliferate and produce collagen and
other ECM components.
11 0 Endothelial damage would let
leucocytes migrate through the vessels into the extra vascular
tissue and promote the activation of the innate immunity. This
local inflammatory response would be self limiting without the
transition to the adoptive immunity with activation of T cells
that sustain a chronic inflammatory state and stimulate fibrosis
by directly interacting with fibroblasts and producing fibrogenic
mediators, such as interleukin (IL)4, IL13 and transforming
growth factor (TGF)-b1.
1 Focusing on the interplays between
endothelial cells and lymphocytes may be crucial to unravel the
early events occurring in SSc pathogenesis. Circulating T cells
interact with endothelial layer through an intricate system of
receptors and their ligands, generally known as ‘‘adhesion
molecules’’.
2 L-selectin and P-selectin, oligosaccharide proteins
belonging to the family of selectins, are expressed on
T lymphocytes and endothelial cells, respectively, and recipro-
cally interact to allow loose adhesion of circulating lympho-
cytes. If a firm adhesion, which preludes migration through the
vessels into the extra-vascular space, occurs, endothelial cells
and T cells undergo activation and modulate the expression of
their surface receptors.
11 ICAM-1 and VCAM-1 are upregulated
on activated endothelial cells and interact with LFA-1 and VLA-4,
respectively, expressed on activated T cells. When over-
expressed on the cell surface, some of these proteins are shed
in biological fluids as a regulatory mechanism, and the soluble
forms, sVCAM-1, sICAM-1 and sP-selectin, can be dosed and
used as markers of endothelial cell activation. Many authors
have shown that serum activation markers are increased in
Figure 1 Percentage of peripheral blood T cells expressing lymphocyte function antigen-1 (LFA-1) (A), very late antigen-4 (VLA-4) (B) and L-selectin
(C) in healthy donors (HD), patients with systemic sclerosis (SSc) without pulmonary arterial hypertension and patients with SSc with pulmonary
arterial hypertension (SSc-PAH) at baseline (t 0), after 6 months (t 6) and 12 months (t 12) of bosentan therapy. Values are mean (SD).
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disease activity.
3 12–19
Among the array of cytokines involved, ET-1, mainly released
by endothelial cells, has been shown to play a physiological role
in controlling vascular tone by regulating vasodilatation and
vasoconstriction. In SSc, changes of crosstalk between ET-1 and
its receptors due to a different distribution of ETA and ETB
receptors break down this balance, causing vasoconstriction to
predominate. Besides vascular tone alterations, ET-1 stimulates
smooth muscle cells and myofibroblasts and promote vasopro-
liferative changes leading to increased pulmonary vasculature
resistances and subsequent PAH.
5 The importance of ET-1 in
the pathogenesis of PAH is further corroborated by the
beneficial effects of the dual endothelin receptors inhibitor,
bosentan, in the treatment of PAH.
72 0
In this study we evaluated the expression of LFA-1, VLA-4
and L-selectin antigens on circulating T cells and serum levels of
soluble vWF, ICAM-1, VCAM-1 and P-selectin in patients with
SSc with associated PAH, at baseline and after 12 months of
bosentan therapy, as compared to patients with SSc without
PAH and healthy subjects. Our results confirm that bosentan
treatment improves exercise ability and dyspnoea in patients
with SSc-PAH,
7 and provide further evidence that endothelial
activation occurs in SSc, since soluble endothelial activation
markers were significantly higher in the whole SSc group than
in controls. Interestingly, whereas vWF antigen levels did not
change after bosentan therapy, serum levels of sICAM-1,
sVCAM-1, sPECAM and sP-selectin fell to normal values
following blocking of the ETA and ETB receptors. These findings
are apparently in contrast with those recently reported by
Sfikakis et al who did not detect changes in sICAM-1 levels in
patients with SSc following bosentan treatment.
21 However, the
latter was a short-term study in which sICAM-1 was assessed in
10 patients with SSc treated with bosentan at lower dosage for
4 months.
The behaviour of T cell subsets bearing adhesion molecules
was noteworthy. T cells expressing LFA-1, the counter-receptor
of ICAM-1, were significantly and selectively enhanced in the
SSc-PAH group at baseline, and LFA-1 expression was down-
regulated by bosentan therapy. The reduction of VLA-4 on
T cells from patients with SSc-PAH was unforeseen as its
expression is expected to increase on activated T cells and the
meaning of these findings is unknown. VLA-4 has pleiotropic
functions and it is involved in T cells/endothelial cells
interactions as well as in T cells/stromal cells interplay. The
finding that VLA-4 was selectively reduced on peripheral T cells
from patients with SSc-PAH but not in patients with SSc
without PAH and HD, suggests that this molecule may be
Figure 2 Fluorescence intensity for CD3–L-selectin cell subset from a patient with SSc-PAH at baseline and after 12 months of bosentan therapy
(upper panels), from a patient with SSc without PAH (middle panels) and from a healthy donor (lower panels). Negative control histograms (a
fluorescent non-binding mAb) are shown on the left. The longitudinal axis shows the percentage of lymphocytes positive for CD3 and L-selectin and the
horizontal axis the mean channel fluorescence.
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bosentan did not modify VLA-4 expression on T cells, it is
conceivable that ET-1 does not regulate VLA-4. The pattern of
L-selectin was remarkable in that its expression on T cells was
lower in patients with SSc-PAH than in healthy donors or
patients with SSc without PAH, and strikingly increased to
normal values after bosentan treatment. These data suggest
that bosentan, a dual endothelin receptor antagonist approved
for the therapy of PAH, is able to restore T cell functions in
patients with SSc with PAH in vivo. We can speculate that
blocking both ET-1 receptors can antagonise the detrimental
effects of the imbalance of the ET-1 system in SSc. How
inhibition of ET-1 receptors may regulate LFA-1 and L-selectin
expression on circulating T cells can only be a matter of
speculation at the moment. This may be indirectly mediated by
the microvasculature, which expresses ETA and ETB receptors,
and changes of adhesion molecules on endothelial cells might
modify the expression of their respective ligands on circulating
T cells. Additionally, it may be assumed that T cells may bear
ET-1 receptors on their membrane and that the changes of LFA-1
and L-selectin expression we detected in our patients with
SSc-PAH are due to downstream signals following direct
stimulation by ET-1, subsequently inhibited by bosentan.
This hypothesis needs to be verified by further studies in
vitro addressed to show the expression of ET-1 receptors by T
cells and the role of ET-1 in modulating T cell phenotype.
However, an analogous mechanism has already been shown
on human neutrophils. ET-1 downregulated the expression of
L-selectin and upregulated the expression of LFA-2 on
neutrophils and these effects were selectively prevented by a
specific ETA receptor antagonist.
22 These data seem to be
consistent with our results and coherent with the sequential
two-step action of these molecules. Resting leucocytes highly
express L-selectin and loosely adhere to endothelial cells, the so-
called ‘‘tethering’’, and roll on the endothelial layer. After
activation, endothelial cells upregulate ICAM-1 and leucocytes
downregulate L-selectin and simultaneously increase LFA-1
expression. LFA-1/ICAM-1 interactions would lead leucocytes
to firmly adhere and migrate through the vessels. Furthermore,
LFA-1/ICAM-1 ligation may be involved in T cells/fibroblasts
interactions. In SSc-PAH, ET-1 could stimulate these events on
T cells, which become activated, with high LFA-1 and low L-
selectin expression, and migrate in the extra-vascular space,
while bosentan down-modulates these processes and prevents
further priming of circulating naı ¨ve T cells. However, it should
be taken into account that dermal fibroblasts may be a further
source of increased serum levels of adhesion molecules. ICAM-1
expression on surface fibroblasts is modulated by ET-1 and
inflammatory cytokines, is involved in cell–cell and cell–matrix
interactions and plays a key role in regulating inflammatory
cells binding to dermal tissue.
23 24
In conclusion, this study provides evidence that ET-1 can
induce changes in the T cell/endothelium interplay in SSc-
associated PHA and that blocking ET-1 by the administration of
bosentan can restore these interactions.
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Figure 3 Serum levels of soluble von Willebrand Factor (vWF) (A), P-selectin (B), vascular cell adhesion molecule 1 (VCAM-1) (C), intercellular
adhesion molecule-1 (ICAM-1) (D) and platelet endothelial cell adhesion molecule-1 (PECAM-1) (E) in healthy donors (HD), patients with systemic
sclerosis (SSc) without pulmonary arterial hypertension and patients with SSc with pulmonary arterial hypertension (SSc-PAH) at baseline (t 0) and
after 12 months (t 12) of bosentan therapy. Values are mean SD).
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